Results 251 to 260 of about 259,973 (292)

A Catalytic Osmium Redox Couple Collapses Cancer Redox Balance

Advanced Science, EarlyView.
A stable Os(III)/Os(IV) redox couple is developed to disrupt the tumor cell redox balance by concurrently catalyzing ROS generation and GSH depletion. Osmium‐treated cells exhibit multiple cell death pathways, including apoptosis, ferroptosis, and immunogenic cell death.
Wan‐Qiong Huang, Tao Huang, Yiming Hao, Gui‐Feng Huang, Yi‐Lang Yan, Xin Fang, Ying Chen, Xiao‐Long Wei, Wai‐Lun Man, Wen‐Xiu Ni   +9 more
wiley   +1 more source

Dual biomarker role of PD-L1 and LC3B in glioblastoma: prognostic and therapeutic potential. [PDF]

Neurosurg Rev
Torky RF, Makboul R, Badary DM, El-Ghani WMA, El-Hakeem A, El Ghorori RMH.   +5 more
europepmc   +1 more source

Real‐World Treatment and Outcomes in Resectable Early‐Stage Non‐Small Cell Cancer: THASSOS‐INTL Australia Cohort

AGING MEDICINE, EarlyView.
Australia cohort of THASSOS‐INTL; non‐interventional, multicenter, retrospective study provides insights into treatment patterns and associated survival outcomes in patients with resectable stage I‐III NSCLC in the pre‐immunotherapy era. Neoadjuvant and adjuvant therapy was reported in < 10% and < 40% patients, respectively.
Pei Ding, Kevin Jasas, Victoria Bray, Abhijit Pal, Rebecca Moor   +4 more
wiley   +1 more source

Immune landscape of muscle-invasive bladder cancer: role of TIGIT, LAG-3, and PD-L1. [PDF]

Front Immunol
Knežević M, Tomašković I, Murgić J, Vrhovec B, Dumbović L, Vrbić V, Trifunić S, Milošević M, Ulamec M.   +8 more
europepmc   +1 more source

Association of HAMP Expression and CD8+ T‐Cell Infiltration With Atezolizumab–Bevacizumab Response in Hepatocellular Carcinoma

Annals of Gastroenterological Surgery, EarlyView.
In hepatocellular carcinoma treated with atezolizumab–bevacizumab, responders showed RNA‐seq enrichment of immune and chemokine pathways with higher HAMP expression. In resected specimens, immunohistochemistry confirmed increased intratumoral CD8+ T‐cell density and hepcidin (HAMP), supporting HAMP plus CD8 as components of a composite predictor of ...
Shun Nakamura, Yuki Murakami, Yusuke Oshima, Takashi Masuda, Wataru Miyoshino, Hiroomi Takayama, Yoko Kawano, Teijiro Hirashita, Yuichi Endo, Masafumi Inomata   +9 more
wiley   +1 more source

Leveraging vascular normalization <i>via</i> eNOS activation to enhance the efficacy of PD-L1 blockade. [PDF]

Acta Pharm Sin B
Zhou Y, Gao H.
europepmc   +1 more source

Advances in Gastric Cancer Research: Insights Into Carcinogenesis, the Tumor Microenvironment, Metastasis, and Factors Influencing Prognosis

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background The Department of Gastroenterological Surgery at Kumamoto University has maintained a commitment to integrating cutting‐edge clinical practice with fundamental research, particularly concerning malignant diseases of the digestive tract.
Hideo Baba, Takatsugu Ishimoto, Yoshifumi Baba, Hiromitsu Hayashi, Masaaki Iwatsuki   +4 more
wiley   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Gut Associated Metabolites Enhance PD-L1 Blockade Efficacy in Prostate Cancer. [PDF]

Oncol Res
Liu K, Xue X, Qin H, Zhu J, Jin M, Dai D, Tang Y, Bukhari I, Liu H, Qiu C, Ren F, Zheng P, Mi Y, Chen W.   +13 more
europepmc   +1 more source